Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ISC 2018: DEFUSE 3 Results Bring DAWN Of New Stroke Guidelines

Executive Summary

Results of the DEFUSE 3 trial presented at the International Stroke Conference in Los Angeles, along with the previously announced DAWN trial results, support a new recommendation in the American Heart Association/American Stroke Association guidelines on early management of acute ischemic stroke, extending the viable treatment window from six hours to 24 hours in some patients. The change could drive thrombectomy uptake and an aspiration-first approach.


Related Content

Stryker Pushes For Changes To Stroke Care After DAWN
Global Approvals Analysis: Eight Brain Device Approvals Mark Neurotech November
Stryker's DAWN Thrombectomy Trial Could Also Help Medtronic And Penumbra


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts